HOME >> MEDICINE >> NEWS
European trial finds old lung cancer treatment may still be best

The first clinical trial to compare directly two of the most widely-used drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) have concluded that the older drug, cisplatin, is the better treatment.

Patients given cisplatin and paclitaxel had better survival rates and their quality of life was just as good as patients receiving carboplatin and paclitaxel.

The phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer (NSCLC) is reported in the new issue of Annals of Oncology.*

Cisplatin tends to be the preferred standard chemotherapy for lung cancer in Europe, but in the USA carboplatin is normally used. The new findings are in contrast to a recent similar study in the USA** where a four-arm trial comparing a range of treatments showed no advantage for any one chemotherapy combination over another.

In the European trial the response rates to the two treatments were similar - 28% in the cisplatin/paclitaxel arm and 25% in the carboplatin/paclitaxel arm, but the median survival in the cisplatin arm was significantly better at 9.8 months compared with 8.5 months. The one-year survival rate was 38% in the cisplatin/paclitaxel arm compared with 33% in the carboplatin/paclitaxel arm and the two-year survival rate was 15% and 9% respectively.

Lead investigator Dr Rafael Rosell from the Hospital Germans Trias i Pujol in Barcelona, Spain said: "This large European randomised study can contribute greatly to resolving the longstanding debate on the superiority of carboplatin or cisplatin-based chemotherapy in lung cancer. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option." However, Dr Rosell stressed that paclitaxel/carboplatin was still a viable alternative.

In an acco
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-153-677-2181
European Society for Medical Oncology
9-Oct-2002


Page: 1 2

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: European trial finds old lung cancer treatment may still best

(Date:7/29/2014)... July 29, 2014 Outsourced coding ... tripling in the number of hospitals contracting for ... 2015 deadline, according to the recently published Black ... leaders, found in the reports “Top Ranked Clinical ... now outsource Clinical documentation audit, review and programming. ...
(Date:7/29/2014)... invested $3.4 million this year to support innovative ... chronic diseases that affect more than 233,000 Canadians. ... research projects across Canada. This diverse research will ... improve our understanding (and potential treatment) of symptoms ... quality of life. , Crohn,s and Colitis ...
(Date:7/29/2014)... CHI-California Healthcare Institute today unveiled a ... C (hep C) epidemic in the U.S., the rise ... reduce human suffering. The report examines key data to ... C, while highlighting the significance of breakthroughs that have ... is a nonprofit, public policy research organization, representing leading ...
(Date:7/29/2014)... Thompson HealthDay Reporter MONDAY, ... virus that continues to rage throughout West Africa poses little ... only spreads through physical touch, and it can,t be spread ... deputy director of the National Center for Emerging & Zoonotic ... Prevention, explained in a Monday afternoon news conference. Those ...
(Date:7/29/2014)... Ill. By studying the injuries and aptitudes of ... the war, scientists are tackling -- and beginning to ... , The researchers found that brain regions that contribute ... intelligence and to emotional intelligence. This finding bolsters the ... social context of one,s life. , The ...
Breaking Medicine News(10 mins):Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3Health News:Prestigious Crohn's and Colitis Canada grants fund promising Canadian research 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4Health News:Team studies the social origins of intelligence in the brain 2Health News:Team studies the social origins of intelligence in the brain 3
(Date:7/29/2014)... CITY , July 29, 2014  The ... Grand American Hotel in Salt Lake City ... representing some of most respected healthcare organizations in the ... Catalyst , is an industry conference devoted to providing ... analytics,  an essential element of both accountable care initiatives ...
(Date:7/29/2014)... , July 29, 2014  Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, ... second quarter operational results after closing of the NASDAQ ... A conference call hosted by Michael Martino ... management will take place on the same day at ...
(Date:7/29/2014)... TRIANGLE PARK, N.C. , July 29, 2014 ... on cloud-based drug design and development, announced today ... grant from the National Science Foundation Small Business ... valued at $150,000. Cloud Pharmaceuticals ... the development process by implementing new, innovative cloud ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2
Cached News: